Beckley Psytech Limited Appoints Dr. Laura Trespidi as Chief Development Officer
Beckley Psytech Limited has named Dr. Laura Trespidi as Chief Development Officer. Dr. Trespidi has over 30 years of experience in global pharmaceutical and biotechnology companies, ranging from pre-clinical research to market approvals and global product launches. Dr. Trespidi most recently served as Summit Therapeutics’ Senior Vice President, Chemistry, Manufacturing, and Controls (CMC), Supply Chain, and Technical Operations, where he successfully led global CMC and External Manufacturing teams through the development and market readiness of investigational medicines, including end-to-end supply chain and manufacturing readiness and expansion. Her experience also includes formulation development, technology transfers, outsourcing, and offshoring, as well as developing and implementing change management strategies.
Beckley Psytech is dedicated to helping patients suffering from neurological and psychiatric disorders by developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines.
UK-based Beckley Psytech has completed an oversubscribed Series B financing round, raising £58m ($80m) from venture capital (VC) investors.